Entacapone and selegiline with L-dopa in patients with Parkinson's disease: An interaction study

Parkinsonism and Related Disorders

Volumn 6, Issue 4, 2000, Pages 215-222

  Lyytinen, J ^a   Kaakkola, S ^a   Gordin, A ^b   Kultalahti, E R ^b   Teravainen H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Catechol O methyltransferase; Entacapone; Interaction; Parkinson's disease; Selegiline

Indexed keywords

BENSERAZIDE; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; FLUDROCORTISONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; SELEGILINE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSTONIA; ELECTROCARDIOGRAM; FEMALE; HEART PALPITATION; HEMODYNAMICS; HUMAN; INSOMNIA; MALE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDING; VERTIGO; XEROSTOMIA;

EID: 0033934604     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(00)00012-2     Document Type: Article

References (26)

1. Marsden C.D. Late levodopa failure-pathophysiology and management. Poewe W., Lees A.J. 20 years of Madopar-new avenues. 1993;65-76 Editiones Roche, Basel.
2. Fahn S. Adverse effects of levodopa. Olanow C.W., Lieberman A.N. The scientific basis for the treatment of Parkinson's disease. 1992;89-112 Parthenon, Carnforth.
3. Nutt J.G., Woodward W.R., Beckner R.M. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 44:1994;913-919.
4. Nissinen E., Lindén I.-B., Schultz E., Pohto P. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedeberg's Arch Pharmacol. 346:1992;262-266.
5. Merello M., Lees A.J., Webster R., Bovingdon M., Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 57:1994;186-189.
6. Ruottinen H.M., Rinne U.K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 60:1996;36-40.
7. Ruottinen H.M., Rinne U.K. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol. 19:1996;222-233.
8. Entacapone improves motor fluctuations in L-dopa-treated Parkinson's disease patients. Ann Neurol. 42:1997;747-755.
9. Kaakkola S., Teräväinen H., Ahtila S., Rita H., Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and L-dopa metabolism in parkinsonian patients. Neurology. 44:1994;77-80.
10. Sundberg S., Scheinin M., Illi A. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol. 36:1993;451-456.
11. Illi A., Sundberg S., Koulu M. COMT inhibition by high-dose entacapone does not affect haemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther. 32:1994;582-588.
12. Myllylä V.V., Sotaniemi K.A., Illi A., Suominen K., Keränen T. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol. 45:1993;419-423.
13. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 328:1993;176-183.
14. DATATOP: a multicenter controlled trial in early Parkinson's disease. Arch Neurol. 46:1989;1052-1060.
15. Golbe L.I. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology. 39:1989;1109-1111.
16. Lyytinen J., Kaakkola S., Ahtila S., Tuomainen P., Teräväinen H. Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease. Mov Disord. 12:1997;497-505.
17. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
18. Fahn S., Elton R. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Fahn S., Marsden C.D., Calne D., Goldstein M. Recent developments in Parkinson's disease. 1987;153-163 Macmillan Healthcare Information, New Jersey.
19. Birkmayer W., Riederer P., Yuodim M.B.H., Linauer W. The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm. 36:1975;303-326.
20. Rinne U.K., Larsen J.P., Siden Å. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology. 51:1998;1309-1314.
21. Kuroiwa Y., Shimada Y., Toyokura Y. Postural hypotension and low R-R interval variability in parkinsonism, spino-cerebellar degeneration, and Shy-Drager syndrome. Neurology. 33:1983;463-467.
22. Camerlingo M., Ferraro B., Gazzaniga G.C. Cardiovascular reflexes in Parkinson's disease: long-term effects of levodopa treatment on de novo patients. Acta Neurol Scand. 81:1990;346-348.
23. Stinson J.C., Pears J.S., Williams A.J. Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers. Br J Clin Pharmacol. 39:1995;651-656.
24. Petch M.C. Lessons from ambulatory electrocardiography. BMJ. 291:1985;617-618.
25. Tetrud J.W., Langston J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 245:1989;519-522.
26. Palfreyman M.G., McDonald I.A., Zreika M. MDL 72.974a: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease. J Neural Transm. 40:1993;101-111.